DOI QR코드

DOI QR Code

Lack of any Prognostic Value of Body Mass Index for Patients Undergoing Chemoradiotherapy for Esophageal Squamous Cell Carcinoma

  • Zhang, Fang (Cancer Centre, the First Hospital of Zibo) ;
  • Wang, Chuan-Sheng (Cancer Centre, the First Hospital of Zibo) ;
  • Sun, Bo (Cancer Centre, the First Hospital of Zibo) ;
  • Tian, Guang-Bo (Cancer Centre, the First Hospital of Zibo) ;
  • Cao, Fang-Li (Cancer Centre, Liaocheng People's Hospital) ;
  • Cheng, Yu-Feng (Department of Radiotherapy, Cancer Centre, Qilu Hospital, Shandong University)
  • Published : 2014.04.01

Abstract

Background: The relationship between body mass index(BMI) and outcomes after chemoradiotherapy(CRT) has not been systematically addressed. The purpose of this study was to evaluate the effect of BMI on survival in patients with esophageal squamous cell carcinoma (ESCC). Materials and Methods: Sixty ESCC cases were retrospectively reviewed in this study. Patient overall survival(OS) and disease-free survival (DFS) were compared between two groups (BMI< $24.00kg/m^2$ and $BMI{\geq}24.00kg/m^2$). Results: There were 41 patients in the low/normal BMI group (BMI< $24.00kg/m^2$) and 19 in the high BMI group ($BMI{\geq}24.00kg/m^2$). No significant differences were observed in patient characteristics between these. We found no difference in 2-year OS and DFS associated with BMI (p=0.763 for OS; p=0.818 for DFS) using the Kaplan-Meier method. Univariate analysis revealed that higher clinical stage was prognostic for worse 2-year OS and DFS, metastasis for 2-year OS, lymph node status for 2-year DFS, while age, gender, smoking, drinking, tumor location and BMI were not prognostic. There were no differences in the 2-year OS (hazard ratio=1.117; p=0.789) and DFS(hazard ratio=1.161; p=0.708) between BMI groups in multivariate analysis, whereas we found statistical differences in the 2-year OS and DFS associated with clinical stage, gender and tumor infiltration (p<0.04), independent of age, smoking, drinking, tumor location, the status of lymph node metastases and BMI. Conclusions: BMI was not associated with survival in patients with ESCC treated with CRT as primary therapy. BMI should not be considered a prognostic factor for patients undergoing CRT for ESCC.

Keywords

References

  1. Carmichael AR (2006). Obesity and prognosis of breast cancer. Obes Rev, 7, 333-40. https://doi.org/10.1111/j.1467-789X.2006.00261.x
  2. Dignam JJ, Polite BN, Yothers G, et al (2006). Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst, 98, 1647-54. https://doi.org/10.1093/jnci/djj442
  3. Eroglu C, Orhan O, Karaca H, et al (2013). The effect of being overweight on survival in patients with gastric cancer undergoing adjuvant chemoradiotherapy. Eur J Cancer Care, 22, 133-40. https://doi.org/10.1111/ecc.12010
  4. Felden JB, Figueiredo AC (2011). Distribution of body fat and breast cancer: a case-control study in the South of Brazil. Cien Saude Colet, 16, 2425-33. https://doi.org/10.1590/S1413-81232011000500011
  5. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  6. Gaudet MM, Patel AV, Sun J, et al (2012). Prospective studies of body mass index with head and neck cancer incidence and mortality. Cancer Epidemiol Biomarkers Prev, 21, 497-503. https://doi.org/10.1158/1055-9965.EPI-11-0935
  7. Grotenhuis BA, Wijnhoven BP, Hotte GJ, et al (2010). Prognostic value of body mass index on short-term and long-term outcome after resection of esophageal cancer. World J Surg, 34, 2621-7. https://doi.org/10.1007/s00268-010-0697-8
  8. Hayashi Y, Correa AM, Hofstetter WL, et al (2010). The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy. Cancer, 116, 5619-27. https://doi.org/10.1002/cncr.25745
  9. Kandaz M, Ertekin MV, Bilici M (2012). Retrospective analysis of patients with esophageal cancer treated with radiotherapy and /or chemoradiotherapy. Tumori, 98, 445-50. https://doi.org/10.1177/030089161209800408
  10. Kaviani A, Neishaboury M, Mohammadzadeh N, Ansari-Damavandi M, Jamei K (2013). Effects of obesity on presentation of breast cancer, lymph node metastasis and patient survival: a retrospective review. Asian Pac J Cancer Prev, 14, 2225-9. https://doi.org/10.7314/APJCP.2013.14.4.2225
  11. Kizer NT, Thaker PH, Gao F, et al (2011). The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer, 117, 948-56. https://doi.org/10.1002/cncr.25544
  12. Matsuo K, Mizoue T, Tanaka K et al (2012). Association between body mass index and the colorectal cancer risk in Japan: pooled analysis of population-based cohort studies in Japan. Ann Oncol, 23, 479-90. https://doi.org/10.1093/annonc/mdr143
  13. McRackan TR, Watkins JM, Herrin AE, et al (2008). Effect of body mass index on chemoradiation outcomes in head and neck cancer. Laryngoscope, 118, 1180-5. https://doi.org/10.1097/MLG.0b013e31816fca5c
  14. Morrison DS, Parr CL, Lam TH, et al (2013). Behavioural and metabolic risk factors for mortality from colon and rectum cancer: analysis of data from the Asia-Pacific Cohort Studies Collaboration. Asian Pac J Cancer Prev, 14, 1083-7. https://doi.org/10.7314/APJCP.2013.14.2.1083
  15. Pelucchi C, Galeone C, Polesel J, et al (2014). Smoking and body mass index and survival in pancreatic cancer patients. Pancreas, 43, 47-52. https://doi.org/10.1097/MPA.0b013e3182a7c74b
  16. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008). Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet, 371, 569-78. https://doi.org/10.1016/S0140-6736(08)60269-X
  17. Samadi F, Babaei M, Yazdanbod A, et al (2007). Survival rate of gastric and esophageal cancers in Ardabil province, North-West of Iran. Arch Iran Med, 10, 32-7.
  18. Schoppmann SF, Jesch B, Zacherl J, et al (2013). Lymphangiogenesis and lymphovascular invasion diminishes prognosis in esophageal cancer. Surgery, 153, 526-34. https://doi.org/10.1016/j.surg.2012.10.007
  19. Shridhar R, Hayman T, Hoffe SE, et al (2012). Body mass index and survival in esophageal adenocarcinoma treated with chemoradiotherapy followed by esophagectomy. J Gastrointest Surg, 16, 1296-302. https://doi.org/10.1007/s11605-012-1843-4
  20. Smith M, Zhou M, Whitlock G, et al (2008). Esophageal cancer and body mass index: results from a prospective study of 220, 000 men in China and a meta-analysis of published studies. Int J Cancer, 122, 1604-10.
  21. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ (2011). American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology, 140, 18-52.
  22. Trivers KF, De Roos AJ, Gammon MD, et al (2005). Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clin Gastroenterol Hepatol, 3, 225-30. https://doi.org/10.1016/S1542-3565(04)00613-5
  23. Wang J, Myles B, Wei C, et al (2014). Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus, 27, 168-75. https://doi.org/10.1111/dote.12074
  24. WHO Expert Consultation (2004). Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet, 363, 157-63. https://doi.org/10.1016/S0140-6736(03)15268-3
  25. Zhang F, Han H, Wang C, et al (2013). A retrospective study: the prognostic value of anemia, smoking and drinking in esophageal squamous cell carcinoma with primary radiotherapy. World J Surg Oncol, 11, 249. https://doi.org/10.1186/1477-7819-11-249